Drugs Made In America Acquisition (DMAAR) Beginning Cash Balance (2025)

Drugs Made In America Acquisition (DMAAR) reported Beginning Cash Balance of $900000.0 for Q1 2025.

Drugs Made In America Acquisition (DMAAR) Beginning Cash Balance (2025) Analysis & Trends

Drugs Made In America Acquisition has reported Beginning Cash Balance for 1 years, with the latest figure at $900000.0 in Q1 2025.

  • For the quarter ending Q1 2025, Beginning Cash Balance changed N/A year-over-year to $900000.0; the trailing twelve-month figure through Dec 2025 stood at $900000.0 (changed N/A YoY), and the FY2025 full-year result was $900000.0, down 30.79% from the prior year.
  • Beginning Cash Balance for Q1 2025 stood at $900000.0.
  • The five-year high for Beginning Cash Balance was $900000.0 in Q1 2025, with the low at $900000.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn -
2 Berto Acquisition 312.46 Mn 312.46 Mn -
3 Centurion Acquisition 311.65 Mn 311.65 Mn -
4 GP-Act III Acquisition 311.36 Mn 311.36 Mn -
5 Churchill Capital Corp IX 310.79 Mn 310.79 Mn -
6 WEN Acquisition 309.15 Mn 309.15 Mn -
7 Bold Eagle Acquisition 275.54 Mn 275.54 Mn -
8 Soulpower Acquisition 264.91 Mn 264.91 Mn -
9 BTC Development 262.16 Mn 262.16 Mn -
10 Drugs Made In America Acquisition - - -

Historic Data

Download Data
DateValue
Mar 31, 2025 900,000.00
Mar 31, 2025 900,000.00